Literature DB >> 26202639

Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion.

Chien-Hung Chen1, Sheng-Nan Lu2, Chuan-Mo Lee2, Chao-Hung Hung2, Jing-Houng Wang2, Tsung-Hui Hu2.   

Abstract

PURPOSE: It remains unclear whether chronic hepatitis B patients who undergo interferon (IFN)-induced hepatitis B e antigen (HBeAg) seroconversion have a higher risk of hepatitis B virus (HBV) reactivation and HBeAg seroreversion than those with spontaneous HBeAg seroconversion.
METHODS: A total of 80 and 251 non-cirrhotic patients with interferon-induced and spontaneous HBeAg seroconversion, respectively, were analyzed.
RESULTS: Compared to spontaneous HBeAg seroconverters, more IFN-induced HBeAg seroconverters were males (p = 0.004). For all patients, the IFN-induced HBeAg seroconverters faced a higher risk of HBV reactivation and HBeAg seroreversion than spontaneous HBeAg seroconverters (p < 0.001). For spontaneous HBeAg seroconverters, age at HBeAg seroconversion, male sex, HBV genotype C, and pre-S deletions were independent predictors of HBV reactivation. For IFN-induced HBeAg seroconverters, older age at baseline and HBV genotype C were independent predictors of HBV reactivation. To determine whether the difference in the rates of HBV reactivation or HBeAg seroreversion between two groups was age-dependent, patients were grouped and analyzed according to their age at HBeAg seroconversion (20-30, 31-39, ≥40 years). IFNs treatment was an independent factor in HBV reactivation and HBeAg seroreversion only in the groups of patients 31-39 and ≥40 years of age, but not in the group of patients 20-30 years of age.
CONCLUSIONS: IFN-induced rather than spontaneous HBeAg seroconversion was associated with higher risk of HBV reactivation and HBeAg seroreversion, especially in patients who were older than 30 years at HBeAg seroconversion.

Entities:  

Keywords:  HBV reactivation; HBeAg seroconversion; HBeAg seroreversion; Hepatitis B virus; Interferon

Year:  2014        PMID: 26202639     DOI: 10.1007/s12072-014-9542-8

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  34 in total

Review 1.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

2.  Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Kenneth Kar-Lung Yan; Angel Mei-Ling Chim; Hoi-Yun Chan; Chi-Hang Tse; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

3.  Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

Authors:  Tai-Chung Tseng; Chun-Jen Liu; Tung-Hung Su; Chia-Chi Wang; Chi-Ling Chen; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

4.  Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan.

Authors:  Chien-Hung Chen; Chuan-Mo Lee; Sheng-Nan Lu; Chi-Sin Changchien; Hock-Liew Eng; Chao-Min Huang; Jing-Houng Wang; Chao-Hung Hung; Tsung-Hui Hu
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

Authors:  Teerha Piratvisuth; George Lau; You-Chen Chao; Rui Jin; Anuchit Chutaputti; Q-B Zhang; Tawesak Tanwandee; Peter Button; Matei Popescu
Journal:  Hepatol Int       Date:  2008-02-05       Impact factor: 6.047

6.  Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.

Authors:  S M Lin; I S Sheen; R N Chien; C M Chu; Y F Liaw
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

7.  Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion.

Authors:  Chien-Hung Chen; Chuan-Mo Lee; Jing-Houng Wang; Tsung-Hui Hu; Chao-Hung Hung; Chi-Sin Changchien; Sheng-Nan Lu
Journal:  Hepatol Int       Date:  2012-06-21       Impact factor: 6.047

8.  Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan.

Authors:  C M Lee; C H Chen; S N Lu; H D Tung; W J Chou; J H Wang; T M Chen; C H Hung; C C Huang; W J Chen
Journal:  Scand J Gastroenterol       Date:  2003-01       Impact factor: 2.423

Review 9.  Global control of hepatitis B virus infection.

Authors:  Jia-Horng Kao; Ding-Shinn Chen
Journal:  Lancet Infect Dis       Date:  2002-07       Impact factor: 25.071

10.  Precore mutant hepatitis B virus infection and liver disease.

Authors:  N V Naoumov; R Schneider; T Grötzinger; M C Jung; S Miska; G R Pape; H Will
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

View more
  3 in total

1.  Interferon for Chinese patients with chronic hepatitis B e antigen-positive diseases-the controversy arises again?

Authors:  George K K Lau
Journal:  Hepatol Int       Date:  2014-07-09       Impact factor: 6.047

2.  Towards Genotype-Specific Care for Chronic Hepatitis B: The First 6 Years Follow Up From the CHARM Cohort Study.

Authors:  Jane Davies; Emma L Smith; Margaret Littlejohn; Rosalind Edwards; Vitina Sozzi; Kathy Jackson; Katie Mcguire; Paula Binks; Benjamin C Cowie; Stephen Locarnini; Joshua S Davis; Steven Y C Tong
Journal:  Open Forum Infect Dis       Date:  2019-11-03       Impact factor: 3.835

Review 3.  Recent Advances in HBV Reactivation Research.

Authors:  Lixia Guo; Dan Wang; Xiping Ouyang; Ni Tang; Xuemei Chen; Yuhong Zhang; Hongquan Zhu; Xiaosong Li
Journal:  Biomed Res Int       Date:  2018-12-26       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.